Orano Med

IN THE PRESS

Press Releases

Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas

June 27, 2025

·

4 min read

Press Releases

Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

October 17, 2024

·

9 min read

Press Releases

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

September 12, 2024

·

10 min read

Policy

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors First Targeted Alpha Therapy to receive a Breakthrough Therapy Designation

February 12, 2024

·

5 min read

Business

Orano Med and Orbit Discovery Enter Collaboration to Discover Novel Targeted Radioligand Therapies for Cancer

September 11, 2023

·

2 min read

Drug Development

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

May 16, 2023

·

5 min read

Business

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

May 11, 2023

·

7 min read

Drug Development

Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors

January 4, 2023

·

4 min read

Business

Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers

January 3, 2022

·

4 min read

JOBS